Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022 - A Hybrid Seminar

This seminar series will address emerging diagnostic and treatment approaches for Viral Hepatitis (Hep A, B, C, Delta and E) and Chronic Diseases of the Liver (Cirrhosis, Hepatocellular Carcinoma, Hepatic Encephalopathy, Primary Biliary Cholangitis (PBC) and Fatty Liver Disease. Time will also be spent on complications of cirrhosis, hepatorenal syndrome and liver health needs of special populations.
When Feb 26, 2022 07:00 AM to
Oct 15, 2022 04:15 PM
Where Various Dates and Locations - See Below
Contact Name
Add event to calendarvCal
iCal


 The goal of this seminar series is to prevent new cases and improve the outcomes of those already infected. This completely updated seminar series will be offered in 10 cities across the country beginning in February 2022.
A new module of impact of COVID-19 on the liver and patients with liver disease has been added to this program

In addition to the face-to-face and live streaming webinars seminars, the content is also available as an web-based enduring material.

Target Audience
Gastroenterologists, Internists, Hepatologists, family physicians, clinical pharmacists as well as related advanced-practice clinicians and nurse specialists.

Program Agenda

Seminar Brochure

Hepatitis and CLD Enduring Material Activity

Registration Fees


Register
Click on a date and location below to register for a program.

If online registration has closed you may still attend the event by registering as a walk-in the day of the program.



February 26, 2022 - Pasadena, CA
Tse Ling Fong, MD – USC Keck School of Medline
Sammy Saab, MD – UCLA School of Medicine
Lucy Mathew, ACNP-BC –Cedars Sinai Medical Center

March 5, 2022 - Louisville, KY
Craig McClain, MD – University of Louisville School of Medicine
Matt Cave, MD – University of Louisville School of Medicine
Anotosh Barve, MD – University of Louisville School of Medicine
Barbra Cave, PA – University of Louisville Hospital
Loretta Jophlin, MD, PhD - University of Louisville School of Medicine

March 19, 2022 - Raleigh, NC
Sidney Barritt, IV, MD - University of North Carolina
Andrew Muir, MD - Duke University
Elizabeth Goacher, PA-C - Duke University Hospital

April 2, 2022 - Houston, TX
Saira Khaderi, MD, MPH  - Baylor University School of Medicine
Victor Machicao, MD – University of Texas HSC
Line Hiojosa, FNP - BC Baylor College of Medicine

April 30, 2022 - Denver, CO
Lisa Forman, MD - University of Colorado School of Medicine
Avash Kalra, MD - University of Colorado School of Medicine
Michael Ball, PharmD - Presbyterian/St Luke’s Hospital

May 14, 2022 - Costa Mesa, CA
Tse Ling Fong, MD - USC Keck School of Medicine
Mazan Nourredin, MD
-  Cedars-Sinai Medical Center
Tammy Harper, PA-C – USC Keck School of Medicine

June 4, 2022 - Richmond, VA
Mitchell Schiffman, MD - Bon Secours Liver Institute of Richmond
Josmoshan Bajaj, MD – Virginia Commonwealth University Health
Sarah Hubbard, PC-C – Liver Institute of Virginia

October 1, 2022 - Indianapolis, IN
Kenneth Sherman, MD – University of Cincinnati
Naga Chalasani, MD – Indiana University
Carrie Jennings, NP - UC Health Medical Center

October 8, 2022 - San Diego, CA
Catherine Frenette, MD – Scripps Health
Robert Gish, MD – Hepatitis B Foundation
Susan Sommer, NP – UC San Diego Hospital

Joint Provider Statement
 This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortia. The University of Louisville School of Medicine is accredited by the ACCME to provide continuing education for physicians.

Designation Statement

 The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credit(s)™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1264. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Jointly Provided By

Acknowledgments
We thank our supporting and exhibiting companies for their participation in the Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022. A final listing of supporters and exhibitors will be available at the meeting sessions.

Disclosure of Ineligible Company Support
This activity has been supported by educational grants from the following:

CME Enduring Material Activity (Available Soon)

Welcome to On-line version of the Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022. The content will address emerging diagnostic and treatment approaches for Viral Hepatitis (Hep A, B, C, Delta and E) and Chronic Diseases of the Liver (Cirrhosis, Hepatocellular Carcinoma, Hepatic Encephalopathy, Primary Biliary Cholangitis (PBC) and Fatty Liver Disease. Time will also be spent on complications of cirrhosis, hepatorenal syndrome and liver health needs of special populations.

The majority of the course materials reside on our digital app and you will be provided log-on information and credentials.  When you have completed the course work, you will be directed to a site to take the required CME quiz, evaluate the seminar, and claim your CME credits.

    ABIM MOC Credit is available for this Enduring Material

Accreditation Disclosure
As a provider accredited by the ACCME, the Office of CME&PD, School of Medicine, University of Louisville, must ensure balance, independence, objectivity, and scientific rigor in all its accredited educational activities. All Planners, faculty, reviewers, and other persons that affected the content of this CME activity were required to submit a financial disclosure form from which relevant conflicts of interest were determined. If any relevant financial relationship(s) with ineligible companies were disclosed, the materials each of them prepared for this program (or influenced) were peer-reviewed and determined to be without ineligible company bias, were considered fair and balanced in terms of therapeutic options, and presented evidence-based content. All relevant financial relationships with ineligible organizations have been mitigated prior to this activity.

Learner Consent Statement
Names or contact information of learners will not be shared with any ineligible company or its agents without the explicit consent of the individual learner.